Home  »  Stocks to Invest   »  Obalon Therapeutics Inc. (OBLN) stock surges in th...

Obalon Therapeutics Inc. (OBLN) stock surges in the pre-market trading. Why is it so?

Obalon Therapeutics Inc. (OBLN) stock gained by 2.9% at the last trading close while the OBLN stock price kept on rising by 16.94% in the pre-market trading session. Obalon Therapeutics is a San Diego-based company that specializes in the development and commercialization of innovative weight-loss technologies.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Recent Important Events

On April 17, 2021, it was being announced that WeissLaw LLP is reviewing alleged violations of fiduciary responsibility and other legal irregularities by Obalon Therapeutics’ board of directors in conjunction with OBLN’s planned merger with ReShape Lifesciences Inc. ReShape will purchase OBLN in an all-stock deal under the terms of the merger agreement, and OBLN will be renamed ReShape Lifesciences Inc.

Financial Results

Around a month back, OBLN announced its financial results for the fourth quarter and full-year 2020. Given below is the summary.

Fourth Quarter 2020

  • OBLN’s revenue for the fourth quarter of 2020 was $0.1 million, whereas for the fourth quarter 2019 the revenue was $0.8 million with the decrease primarily due to the suspension of operations in the second quarter of 2020.
  • Net loss for the fourth quarter of 2020 was $1.3 million, compared to $4.9 million for the fourth quarter of 2019. Net loss per share for the fourth quarter of 2020 was $0.17, compared to $0.64 for the fourth quarter of 2019.
  • In the fourth quarter of 2020, research and development costs were $0.2 million, decreasing from $1.5 million in the fourth quarter of 2019.
  • In the fourth quarter of 2020, selling, general, and administrative expenses fell to $1.2 million, relative to $3.6 million in the fourth quarter of 2019.

Full year 2020

  • OBLN’s revenue for the full year of 2020 was $1.6 million, compared to $3.3 million for the full year of 2019, with the decrease primarily due to the suspension of operations in the second quarter of 2020. Net loss for the full year of 2020 was $12.3 million, compared to $23.7 million for the full year of 2019. Net loss per share for the full year of 2020 was $1.59, compared to $5.03 for the full year of 2019.
  • The total cost of research and development for the full year of 2020 was $2.5 million, down from $6.9 million in the previous year.
  • For the full year of 2020, selling, general, and administrative expenses fell to $8.8 million, down from $16.7 million in 2019.
  • The operating loss for the full year of 2020 was $12.0 million, compared to $23.2 million in the previous year.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Biotech Stocks to Buy for Sep-2021

Biotechnology (biotech) refers to the use of microbes and cellular biology in health-related research and development. It is not just therapies that biotechnology companies develop.

635

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam